We take a layered approach
Deciding between a GLP-1 pill and injection hinges on personal comfort, lifestyle, and insurance coverage
Cardiovascular Risk Reduction: With the 2023 approval for reducing major adverse cardiovascular events, GLP-1 receptor agonists are now used within comprehensive cardiovascular risk-management strategies for patients with type 2 diabetes and established cardiovascular disease
Amy Stobie, a marketing and communications expert whose experience spans FMCG, healthcare, pharmaceuticals, and vitamins, minerals and supplements (VMS), says Chinas Healthy China Initiative, launched in 2019 makes it well-prepared to support citizens who are prescribed GLP-1s for weight loss
Park JS, Nam JS, Cho MH, Yoo JS, Ahn CW, Jee SH, Lee HS, Cha BS, Kim KR, Lee HC
Generationally, 3% were baby boomers, 29% were Gen X, 53% were millennials, and 14% were Gen Z